DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/q6kl94/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering.
This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development (Partial List)
- F. Hoffmann-La Roche Ltd.
- Biogen Idec Inc.
- Athersys, Inc.
- Seattle Genetics, Inc.
- Millennium Pharmaceuticals, Inc.
- Novartis AG
- Idera Pharmaceuticals, Inc.
- Mesoblast Limited
- Jazz Pharmaceuticals plc
- Alexion Pharmaceuticals, Inc.
- Soligenix, Inc.
- NeoStem, Inc.
- Pharmacyclics, Inc.
- Pluristem Therapeutics Inc.
- MediPost Co., Ltd.
- Kamada Ltd.
- R-Tech Ueno, Ltd.
- Omni Bio Pharmaceutical Inc.
- Alder Biopharmaceuticals Inc.
- MSM Protein Technologies, Inc.
For more information visit http://www.researchandmarkets.com/research/q6kl94/graft_versus_host